<DOC>
	<DOC>NCT00661180</DOC>
	<brief_summary>The purpose of this study is to evaluate the anti-cancer activity and safety of Bay 43-006, in patients who have Chronic Myelogenous Leukemia that resisted to Gleevec treatment, one of the standard medication administered for these patients.</brief_summary>
	<brief_title>Open Label Phase II Study of BAY 43-9006 in Chronic Myelogenous Leukemia (CML) Patients Resistant to Gleevec</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia, Myeloid</mesh_term>
	<mesh_term>Leukemia, Myelogenous, Chronic, BCR-ABL Positive</mesh_term>
	<mesh_term>Sorafenib</mesh_term>
	<mesh_term>Imatinib Mesylate</mesh_term>
	<mesh_term>Niacinamide</mesh_term>
	<criteria>Have Philadelphia chromosome positive chronic myelogenous leukemia (CML) in chronic phase, as per IBMTR criteria Have documented hematologic resistance to Gleevec (Imatinib) following a prior hematologic response to Gleevec administered at doses of at least 400 mg/d for at least 3 months. Have WBC &gt;20 x 109/L at study entry Have an ECOG performance status. Status of 0, 1 or 2 Have an anticipated survival of at least 16 weeks. Be able to comply with study procedures and followup examinations. Signed informed consent must be obtained prior to any study specific procedures. Exclusion Criteria: Congestive heart failure &gt; class II as defined by the New York Heart Association Functional Classification (NYHA) Cardiac arrhythmias requiring antiarrythmics (excluding beta blockers or digoxin) Active coronary artery disease or ischemia History of HIV infection or chronic hepatitis B or C Active clinically serious infections (&gt; grade 2 NCICTC) Patients with seizure disorder requiring antiepileptic drugs History of solid organ allograft</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2014</verification_date>
</DOC>